| Therapeutic Drug Monitoring of Orally Administered Letermovir Prophylaxis in Allogeneic Hematopoietic Stem Cell Transplant Recipients | Antimicrobial agents and chemotherapy |  | | 2022 | 108 | 343 |
|
| Letermovir Primary Prophylaxis in High-Risk Hematopoietic Cell Transplant Recipients: A Matched Cohort Study | Vaccines | | | 2021 | 209 | 324 |
|
| Predictors of breakthrough clinically significant cytomegalovirus infection during letermovir prophylaxis in high-risk hematopoietic cell transplant recipients | Immunity, inflammation and disease | | | 2021 | 376 | 245 |
|
